WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 522492

CAS#: 712313-35-4

Description: HAMI 3379 is a selective CysLT2 receptor antagonist. HAMI 3379 protects against acute brain injury after focal cerebral ischemia in rats. HAMI 3379 attenuates ischemia-like neuronal injury by inhibiting microglial activation. HAMI 3379 effectively blocked CysLT2R-mediated microglial activation, thereby indirectly attenuating ischemic neuronal injury. Therefore, CysLT2R antagonists may represent a new type of therapeutic agent in the treatment of ischemic stroke.

Price and Availability


USD 340

USD 590

USD 1200

HAMI3379, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 522492
Name: HAMI3379
CAS#: 712313-35-4
Chemical Formula: C34H45NO8
Exact Mass: 595.31452
Molecular Weight: 595.733
Elemental Analysis: C, 68.55; H, 7.61; N, 2.35; O, 21.48

Synonym: HAMI3379; HAMI-3379; HAMI 3379.

IUPAC/Chemical Name: 3-[[(3-carboxycyclohexyl)amino]carbonyl]-4-[3-[4-[4-(cyclohexyloxy)butoxy]phenyl]propoxy]-benzoic acid


InChi Code: InChI=1S/C34H45NO8/c36-32(35-27-10-6-9-25(22-27)33(37)38)30-23-26(34(39)40)15-18-31(30)43-21-7-8-24-13-16-29(17-14-24)42-20-5-4-19-41-28-11-2-1-3-12-28/h13-18,23,25,27-28H,1-12,19-22H2,(H,35,36)(H,37,38)(H,39,40)


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Xu DM, Zhang XY, Wang XR, Chen L, Zhang LH, Shi QJ, Fang SH, Lu YB, Zhang WP, Wei EQ. [Antioxidative effects of cysteinyl leukotriene receptor antagonists montelukast and HAMI 3379 on ischemic injury in rat cortical neurons in vitro]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2014 May;43(3):257-64. Chinese. PubMed PMID: 24998647.

2: Lin K, Fang S, Cai B, Huang X, Zhang X, Lu Y, Zhang W, Wei E. ERK/Egr-1 signaling pathway is involved in CysLT2 receptor-mediated IL-8 production in HEK293 cells. Eur J Cell Biol. 2014 Jul;93(7):278-88. doi: 10.1016/j.ejcb.2014.05.001. Epub 2014 May 20. PubMed PMID: 24925646.

3: Zhang Z, Luo J, Huang J, Liu Z, Fang S, Zhang WP, Wei E, Lu Y. [Leukotriene D4 activates BV2 microglia in vitro]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2013 May;42(3):253-60. Chinese. PubMed PMID: 23801612.

4: Zhang XY, Wang XR, Xu DM, Yu SY, Shi QJ, Zhang LH, Chen L, Fang SH, Lu YB, Zhang WP, Wei EQ. HAMI 3379, a CysLT2 receptor antagonist, attenuates ischemia-like neuronal injury by inhibiting microglial activation. J Pharmacol Exp Ther. 2013 Aug;346(2):328-41. doi: 10.1124/jpet.113.203604. Epub 2013 Jun 7. PubMed PMID: 23750020.

5: Dong X, Zhao Y, Huang X, Lin K, Chen J, Wei E, Liu T, Hu Y. Structure-based drug design using GPCR homology modeling: toward the discovery of novel selective CysLT2 antagonists. Eur J Med Chem. 2013 Apr;62:754-63. doi: 10.1016/j.ejmech.2013.01.041. Epub 2013 Feb 9. PubMed PMID: 23455026.

6: Shi QJ, Xiao L, Zhao B, Zhang XY, Wang XR, Xu DM, Yu SY, Fang SH, Lu YB, Zhang WP, Sa XY, Wei EQ. Intracerebroventricular injection of HAMI 3379, a selective cysteinyl leukotriene receptor 2 antagonist, protects against acute brain injury after focal cerebral ischemia in rats. Brain Res. 2012 Nov 12;1484:57-67. doi: 10.1016/j.brainres.2012.09.020. Epub 2012 Sep 18. PubMed PMID: 23000196.

7: Wunder F, Tinel H, Kast R, Geerts A, Becker EM, Kolkhof P, Hütter J, Ergüden J, Härter M. Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT(2)) receptor. Br J Pharmacol. 2010 May;160(2):399-409. doi: 10.1111/j.1476-5381.2010.00730.x. PubMed PMID: 20423349; PubMed Central PMCID: PMC2874861.